description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM217.MS_naive_stable.D9, Clinically stable relapsing/remitting MS,.0u, long-term treatment (8MU)


title: SM205.Healthy_Control.C5

status: Public on Sep 27 2019

type: RNA

city: Chicago

first: Riyue

last: Bao

state: IL

address: 900 E 57 Street

department: Center for Research Informatics

country: USA

institute: University of Chicago

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM205.Healthy_Control.C5

hyb_protocol: The fragmented and labeled single stranded cDNA was hybridized to Human Clariom D array for 16 h at 45°C and 60 rpm in an Affymetrix Hybridization Oven 640. Arrays were washed and stained with Streptavidin Phycoerythrin in an Affymetrix Fluidics Station 450 according to Affymetrix  GeneChip WT Plus Reagent Kit guide (Thermo Fisher Scientific, Inc).

scan_protocol: The arrays were scanned using the Affymetrix Gene Chip Scanner 3000 7G and CEL. intensity files were generated by GeneChip Command Console Software (AGCC, Thermo Fisher Scientific, Inc).  The Cel. files were then used to analyze the data with TAC console (Affymetrix).

data_processing: Raw CEL files were imported, log2-transformed, and normalized using GC Correction and Space Transformation Robust Multi-array Average (GC-STT-RMA) algorithms in Affymetrix Power Tools (APT, version 1·17·0).

label: biotin

molecule: total RNA

organism: Homo sapiens

source_name: Human peripheral blood mononuclear cells

label_protocol: 250 ng of total RNA was used to generate double stranded cDNA and cRNA. 5.5ug of single stranded cDNA synthesized from cRNA was fragmented and biotin labeled according to Affymetrix  GeneChip WT Plus Reagent Kit manual (Thermo Fisher Scientific, Inc).

growth_protocol: mononuclear cells, extracted on ficoll gradients

extract_protocol: Total RNA extracted, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN).  Before affymetrix genechip Human ClariomD microarray analysis, the quality and quantity of each RNA sample were checked using a 2100 BioAnalyzer (Agilent, inc). High-quality RNA (RNA integrity number>9.0) was used for whole transcript microarray analysis

treatment_protocol: Blood obtained before, and 4 and 24  h after, in vivo injection of 8 or 16 million units (250 or 500 micrograms)) of interferon-b, subcutaneous.

tag: tissue

value: peripheral blood mononuclear cells

tag: age


description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM214.MS_naive_stable.D6, Clinically stable relapsing/remitting MS,.0u, long-term treatment (8MU)


title: ADT_0B9MX_H3K4me1_ChIPSeq

status: Public on Sep 28 2019

type: SRA

city: Houston

first: Lisha

last: Zhu

state: TX

address: 7000 fannin st

institute: UT Health Science Center at Houston

description: ADT sample 0B9MX H3K4me1

library_source: genomic

data_processing:
ChIP-seq reads were aligned to the human genome using Burrows-Wheeler Alignment ( BWA) with default parameters in bwa aln and bwa samse
Broad peaks were called using MACS version 2 with the following settings:-B --broad --nomodel --extsize 150 -q 0.01 --broad-cutoff 0.05
Genome_build: hg19
Supplementary_files_format_and_content: BROADPEAK file reports peaks with FDR q <0.05

molecule: genomic DNA

source_name: active disease, treated

extract_protocol:
Peripheral blood mononuclear cells (PBMC) were separated from neutrophils and red blood cells by density-gradient centrifugation. Red cells were removed from neutrophils by hypotonic lysis. Neutrophils were crosslinked using 1% formaldehyde in 10 ml PBS for 10 min at room temperature. Crosslinking was quenched by adding 1× glycine.
ChIP was performed following the protocol (Cell Signaling Technologies, Inc.). DNA-sequencing was conducted using the Illumina HiSeq 2500.

tag: cell type

value: neutrophils

tag: disease state

value: Juvenile Idiopathic Arthritis

tag: chip antibody

value: Anti-Histone H3 (mono methyl K4) antibody - ChIP Grade (ab8895)


title: SM189.Partial_Responder.B14, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM189.Partial_Responder.B14, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM190.Partial_Responder.B14, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM190.Partial_Responder.B14, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM187.Partial_Responder.B14, Clinically stable MS, 8MU IFN-beta (250 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM187.Partial_Responder.B14, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 4  h after IFN-b injection


title: SM193.Partial_Responder.B15, Clinically active MS IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM193.Partial_Responder.B15, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM191.Partial_Responder.B14, Clinically stable MS, 16MU IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM191.Partial_Responder.B14, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM195.Partial_Responder.B15, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM195.Partial_Responder.B15, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM198.Partial_Responder.B15, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM198.Partial_Responder.B15, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM177.Partial_Responder.B13, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM177.Partial_Responder.B13, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM178.Partial_Responder.B13, Clinically stable MS, 8MU IFN-beta (250 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM178.Partial_Responder.B13, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 4  h after IFN-b injection


title: SM179.Partial_Responder.B13, Clinically stable MS, 8MU IFN-beta (250 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM179.Partial_Responder.B13, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 24  h after IFN-b injection


title: SM182.Partial_Responder.B13, Clinically stable MS, 16MU IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM182.Partial_Responder.B13, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM183.Partial_Responder.B14, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM183.Partial_Responder.B14, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM185.Partial_Responder.B14, Clinically active MS IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM185.Partial_Responder.B14, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM194.Partial_Responder.B15, Clinically active MS IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM194.Partial_Responder.B15, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM181.Partial_Responder.B13, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM181.Partial_Responder.B13, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM197.Partial_Responder.B15, Clinically stable MS, 8MU IFN-beta (250 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM197.Partial_Responder.B15, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 24  h after IFN-b injection


title: SM180.Partial_Responder.B13, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM180.Partial_Responder.B13, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM184.Partial_Responder.B14, Clinically active MS IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM184.Partial_Responder.B14, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM199.Partial_Responder.B15, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM199.Partial_Responder.B15, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM196.Partial_Responder.B15, Clinically stable MS, 8MU IFN-beta (250 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM196.Partial_Responder.B15, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 4  h after IFN-b injection


title: SM192.Partial_Responder.B15, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM192.Partial_Responder.B15, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM186.Partial_Responder.B14, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM186.Partial_Responder.B14, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM173.Partial_Responder.B12, Clinically stable MS, 16MU IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM173.Partial_Responder.B12, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM174.Partial_Responder.B13, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM174.Partial_Responder.B13, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM172.Partial_Responder.B12, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM172.Partial_Responder.B12, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM176.Partial_Responder.B13, Clinically active MS IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM176.Partial_Responder.B13, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM171.Partial_Responder.B12, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM171.Partial_Responder.B12, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM188.Partial_Responder.B14, Clinically stable MS, 8MU IFN-beta (250 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM188.Partial_Responder.B14, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 24  h after IFN-b injection


title: SM175.Partial_Responder.B13, Clinically active MS IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM175.Partial_Responder.B13, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM170.Partial_Responder.B12, Clinically stable MS, 8MU IFN-beta (250 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM170.Partial_Responder.B12, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 24  h after IFN-b injection


title: SM169.Partial_Responder.B12, Clinically stable MS, 8MU IFN-beta (250 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM169.Partial_Responder.B12, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 4  h after IFN-b injection


title: SM167.Partial_Responder.B12, Clinically active MS IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM167.Partial_Responder.B12, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM165.Partial_Responder.B12, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM165.Partial_Responder.B12, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM164.Partial_Responder.B11, Clinically stable MS, 16MU IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM164.Partial_Responder.B11, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM166.Partial_Responder.B12, Clinically active MS IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM166.Partial_Responder.B12, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM160.Partial_Responder.B11, Clinically stable MS, 8MU IFN-beta (250 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM160.Partial_Responder.B11, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 4  h after IFN-b injection


title: SM168.Partial_Responder.B12, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM168.Partial_Responder.B12, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM157.Partial_Responder.B11, Clinically active MS IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM157.Partial_Responder.B11, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM163.Partial_Responder.B11, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM163.Partial_Responder.B11, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM159.Partial_Responder.B11, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM159.Partial_Responder.B11, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM155.Partial_Responder.B10, Clinically stable MS, 16MU IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM155.Partial_Responder.B10, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM153.Partial_Responder.B10, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM153.Partial_Responder.B10, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM162.Partial_Responder.B11, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM162.Partial_Responder.B11, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM161.Partial_Responder.B11, Clinically stable MS, 8MU IFN-beta (250 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM161.Partial_Responder.B11, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 24  h after IFN-b injection


title: SM156.Partial_Responder.B11, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM156.Partial_Responder.B11, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM154.Partial_Responder.B10, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM154.Partial_Responder.B10, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM146.Partial_Responder.B9, Clinically stable MS, 16MU IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM146.Partial_Responder.B9, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM158.Partial_Responder.B11, Clinically active MS IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM158.Partial_Responder.B11, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM145.Partial_Responder.B9, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM145.Partial_Responder.B9, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM151.Partial_Responder.B10, Clinically stable MS, 8MU IFN-beta (250 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM151.Partial_Responder.B10, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 4  h after IFN-b injection


title: SM147.Partial_Responder.B10, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM147.Partial_Responder.B10, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM148.Partial_Responder.B10, Clinically active MS IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM148.Partial_Responder.B10, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM144.Partial_Responder.B9, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM144.Partial_Responder.B9, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM150.Partial_Responder.B10, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM150.Partial_Responder.B10, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM152.Partial_Responder.B10, Clinically stable MS, 8MU IFN-beta (250 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM152.Partial_Responder.B10, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 24  h after IFN-b injection


title: SM149.Partial_Responder.B10, Clinically active MS IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM149.Partial_Responder.B10, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM139.Partial_Responder.B9, Clinically active MS IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM139.Partial_Responder.B9, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM143.Partial_Responder.B9, Clinically stable MS, 8MU IFN-beta (250 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM143.Partial_Responder.B9, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 24  h after IFN-b injection


title: SM141.Partial_Responder.B9, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM141.Partial_Responder.B9, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM142.Partial_Responder.B9, Clinically stable MS, 8MU IFN-beta (250 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM142.Partial_Responder.B9, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 4  h after IFN-b injection


title: SM140.Partial_Responder.B9, Clinically active MS IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM140.Partial_Responder.B9, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM130.Partial_Responder.B8, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM130.Partial_Responder.B8, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM117.Partial_Responder.B6, Clinically stable MS, 8MU IFN-beta (250 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM117.Partial_Responder.B6, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 24  h after IFN-b injection


title: SM120.Partial_Responder.B6, Clinically stable MS, 16MU IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM120.Partial_Responder.B6, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM135.Partial_Responder.B8, Clinically stable MS, 8MU IFN-beta (250 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM135.Partial_Responder.B8, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 24  h after IFN-b injection


title: SM137.Partial_Responder.B8, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM137.Partial_Responder.B8, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM118.Partial_Responder.B6, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM118.Partial_Responder.B6, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM123.Partial_Responder.B7, Clinically active MS IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM123.Partial_Responder.B7, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM133.Partial_Responder.B8, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM133.Partial_Responder.B8, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM127.Partial_Responder.B7, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM127.Partial_Responder.B7, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM128.Partial_Responder.B7, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM128.Partial_Responder.B7, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM132.Partial_Responder.B8, Clinically active MS IFN-beta (500 ug), 24  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM132.Partial_Responder.B8, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 24  h after IFN-b injection


title: SM122.Partial_Responder.B7, Clinically active MS IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM122.Partial_Responder.B7, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM125.Partial_Responder.B7, Clinically stable MS, 8MU IFN-beta (250 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM125.Partial_Responder.B7, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 4  h after IFN-b injection


title: SM136.Partial_Responder.B8, Clinically stable MS, 16MU IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM136.Partial_Responder.B8, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM115.Partial_Responder.B6, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM115.Partial_Responder.B6, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM119.Partial_Responder.B6, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM119.Partial_Responder.B6, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM138.Partial_Responder.B9, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM138.Partial_Responder.B9, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM110.Partial_Responder.B5, Clinically stable MS, 16MU IFN-beta (500 ug), 4  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM110.Partial_Responder.B5, Clinically stable MS, 16MU (16 million units IFN-b (500 ug)), 4  h after IFN-b injection


title: SM121.Partial_Responder.B7, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM121.Partial_Responder.B7, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection


title: SM124.Partial_Responder.B7, Clinically stable MS, 8MU IFN-beta (250 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM124.Partial_Responder.B7, Clinically stable MS, 8MU (8 million units IFN-b (250 ug)), 0  h after IFN-b injection


title: SM112.Partial_Responder.B6, Clinically active MS IFN-beta (500 ug), 0  h after IFN-beta injection

description:
Total RNA was extracted from each sample, reverse-transcribed, and amplified using the RNeasy Reagent Kit (QIAGEN, Valencia, CA).  Quantitation and integrity of total RNA samples was measured by Agilent 2100 Bioanalyzer. RNA Integrity Number was calculated based on the entire electrophoretic trace of the RNA sample to evaluate the presence or absence of degradation products. Samples were randomized and then 100 ng RNA was hybridized to GeneChip® Human Transcriptome Arrays (HTA) 2·0 according to manufacturer’s instructions (Affymetrix, Santa Clara, CA). One sample with only 60 ng of RNA was assayed with no degradation in signal. HTA identify a broad dynamic range of expression in protein-coding RNAs, long non-coding RNAs (lncRNA, >200bp), and other RNA biotypes, and detect very low-level signals such as lncRNAs and RNAs coding for cytokines and neuroprotective genes.
SM112.Partial_Responder.B6, Clinically active MS (exacerbation), 16MU (16 million units IFN-b (500 ug)), 0  h after IFN-b injection